Medina Hector J, Galvin Eilish M, Dirckx Maaike, Banwarie Preveen, Ubben Johannes F H, Zijlstra Freek J, Klein Jan, Verbrugge Serge J C
Department of Anesthesiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Anesth Analg. 2005 Aug;101(2):365-370. doi: 10.1213/01.ANE.0000159379.54705.84.
This randomized, double-blind study was designed to evaluate analgesic effectiveness and side effects of two remifentanil infusion rates in patients undergoing extracorporeal shock wave lithotripsy (ESWL) for renal stones. We included 200 patients who were administered remifentanil either 0.05 microg x kg(-1) x min(-1) (n = 100) or 0.1 microg x kg(-1) x min(-1) (n = 100) plus demand bolus of 10 microg of remifentanil via a patient-controlled analgesia (PCA) device. No other sedating drugs were given. The frequencies of PCA demands and deliveries were recorded. Arterial blood pressure, oxygen saturation, and respiratory rate were recorded throughout the procedure; postoperative nausea and vomiting (PONV), dizziness, itching, agitation, and respiratory depression were measured posttreatment. Visual analog scale (VAS) scores were taken preoperatively, directly postoperatively, and 30 min after finishing the procedure. There were no statistically significant differences in the frequency of PCA demands and delivered boluses or among perioperative VAS scores. The extent of PONV and frequency of dizziness and itching immediately after and dizziness 30 min after the end of treatment were significantly reduced in the smaller dose group. We conclude that a remifentanil regimen of 0.05 microg x kg(-1) x min(-1) plus 10 microg demands is superior to 0.1 microg x kg(-1) x min(-1) plus demands, as there was no difference in the VAS scores recorded between groups and it has a less frequent incidence of side effects in patients receiving ESWL.
Remifentanil is an appropriate analgesic choice for patients undergoing extracorporeal shock wave lithotripsy (ESWL) therapy, as it has both fast onset and offset times. We studied remifentanil as a sole drug for ESWL and have shown that an infusion rate of 0.05 microg x kg-1 x min-1 plus patient-controlled analgesia demands of 10 microg provides adequate analgesia and has significantly less side effects than a dose of 0.1 microg x kg-1 x min-1 plus 10 microg demands.
本随机双盲研究旨在评估两种瑞芬太尼输注速率在接受肾结石体外冲击波碎石术(ESWL)患者中的镇痛效果和副作用。我们纳入了200例患者,通过患者自控镇痛(PCA)装置给予他们0.05微克/千克⁻¹·分钟⁻¹(n = 100)或0.1微克/千克⁻¹·分钟⁻¹(n = 100)的瑞芬太尼,并追加10微克瑞芬太尼的按需推注。未给予其他镇静药物。记录PCA的需求频率和给药频率。在整个手术过程中记录动脉血压、血氧饱和度和呼吸频率;治疗后测量术后恶心呕吐(PONV)、头晕、瘙痒、躁动和呼吸抑制情况。术前、术后即刻和手术结束后30分钟采用视觉模拟评分(VAS)。PCA的需求频率和给药推注量或围手术期VAS评分之间无统计学显著差异。小剂量组治疗结束后即刻的PONV程度、头晕和瘙痒频率以及30分钟后的头晕频率均显著降低。我们得出结论,0.05微克/千克⁻¹·分钟⁻¹加10微克按需追加剂量的瑞芬太尼方案优于0.1微克/千克⁻¹·分钟⁻¹加按需追加剂量,因为两组记录的VAS评分无差异,且接受ESWL治疗的患者中其副作用发生率较低。
瑞芬太尼起效和消退时间均快,是接受体外冲击波碎石术(ESWL)治疗患者的合适镇痛选择。我们研究了瑞芬太尼作为ESWL的单一药物,结果表明输注速率为0.05微克/千克⁻¹·分钟⁻¹加10微克患者自控镇痛按需追加剂量可提供充分镇痛,且副作用明显少于0.1微克/千克⁻¹·分钟⁻¹加10微克按需追加剂量。